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ABSTRACT: Background: Motor symptoms of
Parkinson’s disease (PD) are caused by degeneration and
progressive loss of nigrostriatal dopamine neurons.
Currently, no cure for this disease is available. Existing
drugs alleviate PD symptoms but fail to halt neu-
rodegeneration. Glial cell line–derived neurotrophic fac-
tor (GDNF) is able to protect and repair dopamine
neurons in vitro and in animal models of PD, but the clini-
cal use of GDNF is complicated by its pharmacokinetic
properties. The present study aimed to evaluate the neu-
ronal effects of a blood-brain-barrier penetrating small
molecule GDNF receptor Rearranged in Transfection
agonist, BT13, in the dopamine system.
Methods: We characterized the ability of BT13 to activate
RET in immortalized cells, to support the survival of cul-
tured dopamine neurons, to protect cultured dopamine
neurons against neurotoxin-induced cell death, to acti-
vate intracellular signaling pathways both in vitro and in
vivo, and to regulate dopamine release in the mouse stria-
tum as well as BT13’s distribution in the brain.
Results: BT13 potently activates RET and downstream sig-
naling cascades such as Extracellular Signal Regulated
Kinase and AKT in immortalized cells. It supports the sur-
vival of cultured dopamine neurons from wild-type but not
from RET-knockout mice. BT13 protects cultured dopa-
mine neurons from 6-Hydroxydopamine (6-OHDA) and
1-methyl-4-phenylpyridinium (MPP+)–induced cell death
only if they express RET. In addition, BT13 is absorbed in
the brain, activates intracellular signaling cascades in dopa-
mine neurons both in vitro and in vivo, and also stimulates
the release of dopamine in themouse striatum.
Conclusion: The GDNF receptor RET agonist BT13 dem-
onstrates the potential for further development of novel
disease-modifying treatments against PD. © 2019 Inter-
national Parkinson and Movement Disorder Society
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Parkinson’s disease (PD) affects 1% to 2% of the popu-
lation older than 60 years of age.1,2 The characteristic
motor symptoms of PD result from the progressive degen-
eration of dopamine neurons in the brain.3,4 PD patients
also suffer frommultiple nonmotor symptoms.4-6 The cur-
rent drugs for PD management are either supplementing
or mimicking endogenous dopamine. Although these
treatments provide symptomatic relief, they neither halt
nor reverse the disease progression and have very little
effect on nonmotor symptoms. Therefore, the major chal-
lenge remains to develop treatments that protect and
restore dopamine neurons in PD patients and alleviate
nonmotor symptoms.
Glial cell line-derived neurotrophic factor (GDNF) and
the related protein neurturin (NRTN), belonging to the
GDNF family ligands (GFLs), promote the survival of cul-
tured nigrostriatal dopamine neurons and protect and
repair them in animalmodels of PD.7-13 GDNF andNRTN
were also tested in patients with PD, but the results of these
trials are controversial.14-22 Recently, it was shown that
both intracranially infused GDNF and adeno-associated
virus vector encoded GDNF increased putamenal
18Fluoro-dopamine uptake suggesting a neurotrophic
effect of GDNF in the treated patients.14,20,21,23 Further-
more, in the recent phase II trial, a post hoc analysis found
9 (43%) patients only in the GDNF-treated group with a
large clinically important motor improvement in the OFF
state.14,20,21 It should also be noted that early-stage PD
patients, in contrast to late-stage patients, might respond
to adeno-associated virus vector encoded NRTN
treatment.24
The clinical utility of GFLs is complicated by their poor
pharmacokinetic properties, necessity for intracranial
delivery via stereotaxic surgery, varying biological activity,
and high price. However, blood-brain barrier penetrating
small-molecule compounds that target the GFL receptor
complex, which consists of receptor tyrosine kinase
REarranged during Transfection (RET) and GDNF family
receptor α (GFRα),25 and mimic GFL biological effects in
dopamine neurons may more easily translate to the clinic.
Such compounds in principle can affect both terminal
regions of dopamine neurons inducing sprouting and their
cell bodies promoting survival, thus producing superior
effects in comparison to GDNF and also alleviate the non-
motor symptoms of PD often caused by degeneration or
dysfunction of GFL-responsive brain and peripheral
neurons.26,27
Previously, we discovered a small molecule, BT13, that
selectively activates GFL receptor-dependent signaling in
immortalized cells, supports sensory neurons, and allevi-
ates neuropathy in rats.28 In the present study, we evalu-
ated the biological effects of BT13 in the dopamine system.
We demonstrate that BT13 activates RET receptor and
supports the survival of cultured dopamine neurons RET-
dependently. It protects RET-expressing cultured dopa-
mine neurons from 6-hydroxydopamine (6-OHDA) and
1-methyl-4-phenylpyridinium (MPP+)–induced cell death.
In addition, BT13 activates intracellular signaling cascades
in dopamine neurons both in vitro and in vivo and stimu-
lates dopamine release in the mouse striatum. Our results
indicate that BT13 can pave a way to the development of a
novel treatment for PD.
Materials and Methods
Experimental procedures are described in detail in the
Supporting Information.
Cell Lines
MG87, MG87RET cells,29 and reporter cell lines cre-
ated on their basis were described previously.30
Plasmids
Full-length human(h) GFRα1 in pcDNA6,30 GFRα2
cDNA in pCR3.1 and enhanced green fluorescent pro-
tein (GFP) cDNA in pEGFP-N1.
Proteins
Human recombinant GDNF for in vitro experiments
from Icosagen AS (Tartu, Estonia), and for in vivo
studies from PeproTech (Rocky Hill, NJ, USA), fibro-
blast growth factor 2 (Basic Fibroblast Growth Factor)
from BioVision Inc. (Milpitas, CA, USA).
BT13
BT13 was synthesized by EvoBlocks Ltd. (Budapest,
Hungary).
Experimental Animals
All animal experiments were carried out according to
the European Community guidelines for the use of
experimental animals and approved by the National
Animal Experiment Board of Finland (license numbers
ESAVI/7551/04.10.07/2013 and ESAVI/198/04.10.07/
2014) for experiments with living animals and the Lab-
oratory Animal Centre of the University of Helsinki
(license number KEK15-022) for collection of E13.5
embryos of NMRI mice.
Genotyping
Mouse embryonic day 13.5 (E13.5) embryos were
genotyped for the presence or absence of RET as
described previously.31
Luciferase Assay
Luciferase assay was performed as described
previously.28,30
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Phosphorylation Assays
RET, ERK, and AKT phosphorylation in response to
BT13 was analyzed in MG87RET cells transfected with
hGFRα1, hGFRα2, and GFP-expressing plasmids as
described previously.28,32
Survival of Naïve and 6-OHDA and MPP+ -
Challenged Wild-Type and RET-Deficient
Dopamine Neurons
The effect of BT13 on the survival of näive, 6-OHDA,
or MPP+ -challenged dopamine neurons was assessed
using methods described previously.33-38
Analysis of phosphorylated ERK (pERK), AKT
(pAKT), and Phospho-Ribosomal Protein S6
(pS6) Levels in the Cultured Dopamine Neurons
Treated With BT13 or GDNF
Midbrain neuron cultures were prepared as described
previously.33,34,36 At 48 hours postplating, cultures were
starved for 4 hours and treated with 1 μM of BT13 and
10 ng/ml of GDNF for 5 minutes for phosphorylated
(p) ERK activation and 1 hour for phosphorylated
(p) AKT. The cells were fixed and probed with tyrosine
hydroxylase (TH), pERK, pAKT, and phospho-ribosomal
protein S6 (pS6, downstream target of AKT) anti-
bodies.28,33 The mean intensity of pERK, pAKT, and
pS6-specific staining in TH-positive cells was measured
using ImageJ software (Media Cybernetics Inc. [Rockville,
MD, USA]) and normalized to the area of dopamine neu-
ronwhere intensity wasmeasured.
Analysis of pERK and pS6 Levels in the Mouse
Brains Treated With BT13 or GDNF
BT13 (103.5 μg [≈100 μg], N = 4; 207 μg [≈200 μg],
N = 4; 517.5 μg [≈500 μg], N = 4; and 776.25 μg [≈750
μg], N = 4) or GDNF (5 or 10 μg [N = 4]) in saline with
0.5% DMSO (vehicle) were stereotactically injected into
the left striatum using similar procedure as for in vivo
microdialysis.39 The right striatum was injected with the
vehicle. The striatal brain sections collected 1 hour after
the injection were probed with pERK and pS6 anti-
bodies.28 Optical density of pERK and pS6-specific
staining was measured in both hemispheres using ImageJ
software (Media Cybernetics Inc.) and normalized to the
area of the analyzed selection. For presentation purposes,
the values for the BT13-treated and GDNF-treated sides
were normalized to the values for vehicle-treated side of
the same brain.
In Vivo Microdialysis
In vivo microdialysis was performed exactly as
described previously.39
Pharmacokinetics of BT13 and Its Effects on
the Levels of Dopamine Metabolites in the
Midbrain
An analysis of BT13 concentrations in the brain and
plasma at 0.5 to 2 hours postintravenous administration
was conducted by Pharmidex Pharmaceutical Services Ltd
(London, UK) using Ultra High Performance Liquid Chro-
matography/Liquid Chromatography-Mass Spectrometry
(UHPLC/LCMS) methods. The concentration of dopa-
mine, 4-dihydroxyphenylacetic acid (DOPAC), and
homovanillic acid (HVA) was measured in midbrain sam-
ples byHigh Performance Liquid Chromatography.
Statistical Analysis
The data were subjected to statistical analysis using the
Student’s t test or 1-way analysis of variance (ANOVA)
with a Dunnett’s post hoc test in GraphPad Prism 6 (Gra-
phPad Software Inc. [San Diego, CA, USA]).
Results
BT13 Stimulates RET Phosphorylation and
Downstream Intracellular Signaling in
Immortalized Cells
Dopamine neurons respond to GDNF10 and NRTN40
that signal via GFRα1/RET and GFRα2/RET, respec-
tively.25 We evaluated the ability of BT13 to activate
and signal via GFL receptors.
In the cells expressing GFRα1/RET, 25 μM BT13
increased the level of phosphorylated RET by 1.2 fold
(P = 0.0116), 50 μM by 1.4 fold (P < 0.0001), and
100 μM by 1.9 fold (P < 0.0001). In the cells expressing
GFRα2/RET, 25 μM BT13 increased the level of pRET
by 1.3 fold (P = 0.0088), 50 μM by 1.6 fold
(P < 0.0001), and 100 μM by 2.1 fold (P < 0.0001). In
the cells expressing GFP/RET, an increased level of pRET
was observed in response to 50 μM (1.7-fold increase,
P < 0.0001) and 100 μM (2.1-fold increase, P < 0.0001,
1-way ANOVA with Dunnett’s post hoc test for all com-
parisons) BT13 (Fig. 1A-F). Cells responded in the
expected manner to GDNF, NRTN, or soluble GFRα1/
GDNF complex which were used as positive controls.
GDNF-dependent and NRTN-dependent autophosp-
horylation of RET causes activation of downstream
signaling pathways, in particular ERK and AKT,25 impor-
tant for the survival, regeneration, and functioning of neu-
rons. BT13 activated both downstream targets in presence
(GFRα1 transfected and GFRα2 transfected) and absence
(GFP transfected) of GFRα coreceptors (Fig. 1G–I). Cells
responded in the expected manner to GDNF and NRTN
used as positive controls. To provide a quantitative estimate
on the level of intracellular signaling cascade stimulation in
response to BT13, we used luciferase reporter gene-based
assay reflecting the level of ERK activation.30 Consistent
Movement Disorders, Vol. 35, No. 2, 2020 247
G D N F M I M E T I C F O R P A R K I N S O N ’ S M A N A G E M E N T
FIG. 1. BT13 increases phosphorylation of RET (A–C, D–F) and its downstream targets AKT and ERK (G–I, J, K) in immortalized MG87RET fibro-
blasts, but shows no effect in reporter cell line lacking RET (L). Assessment of RET (A–C) and AKT/ERK phosphorylation by WB (G–I), phospho-
RET-Enzyme-Linked Immunosorbent Assay (ELISA) assay to quantify the level of RET phosphorylation (D–F) and activation of luciferase reporter
controlled via ERK by RET (J,K) and fibroblast growth factor receptor (L). Effect of BT13 in MG87RET fibroblasts transfected with GFRα1 (A, D, G,
J), GFRα2, (B, E, H) and GFP (C, F, I, K). Position of molecular weight markers (in kilodaltons, kDA) are shown on the right in A to C and G to
I. Concentrations of GDNF, NRTN, and soluble GFRα1/GDNF complex used as positive controls for GFRα1, GFRα2, and GFP-transfected
MG87RET cells, respectively, and FGF2 in MG87 fibroblast cells are provided in ng/ml. One-way analysis of variance with Dunnett’s post
hoc test. Mean  standard error of mean. Number of experiments (N) = 3 to 4. FGF2, fibroblast growth factor 2; GAPDH, glyceraldehyde-
3-phosphate dehydrogenase, a house-keeping protein, loading control; GDNF, glial cell line–derived neurotrophic factor; GFP, green fluorescent
protein; IP, immunoprecipitation; LCPS, luminescence counts per second; NRTN, neurturin; pERK, phosphorylated ERK; VEH, vehicle; WB, West-
ern blotting. *P < 0.05, **P < 0.01, ***P < 0.0001.
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with Western blotting (Fig. 1G–I) and RET phosphoryla-
tion data (Fig. 1A–F), 25 and 50 μMBT13 increased lucif-
erase activity in the reporter cell lines expressing GFRα1/
RET by 8.6 fold and 11.5 fold, respectively (P < 0.0001)
and in only RET-expressing cells by 11.9 fold (P = 0.0040)
and 21.7 fold, respectively (P < 0.0001, ANOVA with
Dunnett’s post hoc test in all cases; Fig. 1J,K). The differ-
ence in the amplitude of response to BT13 in GFRα1/RET
and RET is likely caused by technical issues in assay setup
(low basal activity of the reporter) as it was not observed in
other assays. It is important to note that in the luciferase
assay, GDNF usually increases reporter activity in GFRα1/
RET–expressing cells by 50 to 100 fold.28,30,33 In the
reporter cell line lacking RET, BT13 failed to influence
luciferase activity while these cells responded as expected to
a cognate inducer, FGF2 (4-fold increase in luciferase activ-
ity, P < 0.0001).
BT13 Supports the Survival of Cultured
Dopamine Neurons
BT13 similarly to GDNF10 can promote the survival of
cultured dopamine neurons. BT13 increased the number
of TH-positive cells in wild-type embryonic midbrain
culture by 1.4 fold (0.1 μM, P < 0.0001) and 1.5 fold
(1 μM, P = 0.0002) and GDNF (10 ng/ml) by 1.8 fold
(P = 0.0207, Repeated Measures (RM) ANOVA with
Dunnett’s post hoc test for all comparisons; Fig. 2A,B). It
is important to note that the bell-shaped dose-response
curves are common for neurotrophic factors in general
and for GDNF in particular.33,41 Both BT13 and GDNF
failed to influence the survival of RET-knockout embry-
onic midbrain dopamine neurons (Fig. 2C), therefore
indicative of their selectivity toward RET.
BT13 Protects Cultured Dopamine Neurons
From 6-OHDA and MPP+ Neurotoxicity Only if
They Express RET
We assessed the neuroprotective ability of BT13 in cul-
tured dopamine neurons treated with dopaminergic toxins.
Treatment with 6-OHDA andMPP+ decreased the number
of survived TH-positive cells in culture by 70% and 30%,
respectively. BT13 similarly to GDNF protected embryonic
midbrain dopamine neurons in culture from both
6-OHDA-induced and MPP+ -induced cell death (Fig. 3A,
B). In the 6-OHDA-treated cultures, 0.1 and 1 μM BT13
increased the number of TH-positive neurons by 1.6 fold
FIG. 2. BT13 similarly to GDNF promotes the survival of cultured primary midbrain dopamine neurons from wild-type (A, B), but not from RET-knockout
mice (C). (A) Representative images of mouse E13.5 wild-type midbrain cultures treated with vehicle, BT13, and GDNF probed with anti-TH antibody,
pseudocolors. (B) The number of TH-positive cells in the wild-type midbrain cultures on the fifth Day in Vitro normalized to the total number of cells in
the culture and presented as percentage of vehicle treated samples. (C) The number of TH-positive cells in the RET-knockout midbrain cultures on the
fifth DIV normalized to the total number of cells in the culture and presented as percentage of vehicle treated samples, average from 3 experiments.
Concentration of GDNF used as a positive control is provided in ng/ml. RM analysis of variance with Dunnett’s post hoc test, mean  standard error of
the mean. Number of independent experiments (N) = 8. Scale bar = 50 μm. DAPI, 40,6-diamidino-2-phenylindole; GDNF, glial cell line–derived neuro-
trophic factor; VEH, vehicle. *P < 0.05, ***P < 0.001, ****P < 0.0001.
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(P = 0.0091) and 1.7 fold (P = 0.0026), respectively, and
GDNF (10 ng/ml) by 1.8 fold (P = 0.0008, 1-way ANOVA
withDunnett’s post hoc test for all comparisons).
Similarly, in the MPP+ toxin model, BT13 (1 μM)
increased the number of TH-positive neurons by 1.3
fold (P = 0.0068) and GDNF (10 ng/ml) by 1.2 fold
(P = 0.0389, 1-way ANOVA with Dunnett’s post hoc
test for all comparisons). In an independent experiment
carried out by Neuron Experts Company (Marseilles,
France) in MPP+ -challenged rat E15 dopamine neu-
rons, BT13 also increased the number of surviving TH-
positive neurons by 13% to 15% (data not shown).
The deletion of RET from cultured dopamine neurons
using Clustered Regularly Interspaced Short Palindromic
Repeats/CRISPR associated protein 9 (CRISPR/
Cas9)-mediated gene editing led to the loss of
neuroprotection from the MPP+ lesion of both BT13 and
GDNF (Fig. 3C). Importantly, in dopamine neurons
treated with CRISPR/Cas9 lentiviral vector carrying
scrambled guide both BT13 and GDNF remained neuro-
protective (Fig. 3D) and increased the number of TH-
positive neurons by 1.7 fold (P = 0.0306 and P = 0.0254,
respectively, 1-way ANOVAwith Dunnett’s post hoc test).
BT13 Stimulates Intracellular Signaling
Important for the Survival and Regeneration of
Cultured Dopamine Neurons
We further measured the mean intensity of pERK, pAKT
and pS6 (downstream target of AKT, for which immuno-
staining produces more robust results compared to AKT
itself42) in cultured dopamine neurons. The duration of
stimulation for each target (5 minutes for pERK and 1 hour
for pAKT and pS6) was chosen in pilot experiment in
which we studied the time course of ERK and S6 activation
in response to GDNF (data not shown). BT13 (1 μM)
increased the mean intensity of pERK (Fig. 4A,C) by 1.7
fold (1 μM, P = 0.0371) and pS6 (Fig. 4B,D) by 1.5 fold
FIG. 3. BT13 protects cultured dopamine neurons from 6-OHDA (A) and MPP+ (B) neurotoxin-induced cell death only when they express RET. The
number of TH-positive cells in the wild-type midbrain cultures treated with 6-OHDA (A) or MPP+ (B). The number of TH-positive cells in midbrain neuron
cultures where RET was deleted using CRISPR/Cas9 gene editing utilizing guide RNA targeting mouse RET (C) or scrambled guide (D). In (A) and (B),
the toxins were added on the 6th DIV, and the number of TH-positive cells was analyzed on the 8th DIV. In (C) and (D), lentiviral vectors were applied
on the 1st DIV, MPP+ on the 8th DIV, and analysis was performed on the 10th DIV. In all cases, the number of TH-positive cells was normalized to the
total number of cells in the culture and presented as percentage of vehicle-treated samples. All experiments were repeated 3 to 6 times with reproduc-
ible results. Concentration of BT13 is in μM and that of GDNF used as a positive control is provided in ng/ml. One-way analysis of variance with
Dunnett’s post hoc test. Mean  standard error of the mean. Number of wells (N) = 4 to 6 (A, B). Number of independent experiments (N) = 4 (C, D).
GDNF, glial cell line–derived neurotrophic factor; MPP+, 1-methyl-4-phenylpyridinium; VEH, vehicle. *P < 0.05, **P < 0.01, ***P < 0.001.
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(P = 0.0307). GDNF increased the mean intensity of pERK
by 2.3 fold (P = 0.0086) and pS6 by 1.7 fold (P = 0.0052,
1-way ANOVA with Dunnett’s post hoc test for all com-
parisons). We also observed an increase in the level of
pAKT in response to both BT13 and GDNF similar to their
effect on pS6 phosphorylation in two experiments (Fig. S2).
BT13 Stimulates Intracellular Signaling
Important for Neuronal Survival and
Regeneration in the Mouse Striatum
We then measured the levels of pERK and pS6 in the
mouse striatum after BT13 injection. Each mouse
received an injection of a vehicle into the right striatum
and BT13 or GDNF into the left striatum (Fig. 5A).
The level of pERK and pS6 staining in vehicle-treated
striata remained unchanged between the treatment
groups (P > 0.05, 1-way ANOVA). BT13 at the dose of
750 μg increased phosphorylation of ERK and S6 com-
pared to the vehicle-treated striatum (P = 0.048 and
P = 0.040, respectively, paired 2-tailed Student’s t test;
Fig. 5B,C). GDNF at the dose of 5 μg elevated levels of
both pERK (P = 0.0266) and pS6 (P = 0.0043) and at
the dose of 10 μg increased phosphorylation of ERK
(P = 0.0085) in the mouse striata.
BT13 Stimulates Release of Dopamine in the
Mouse Striatum
We tested whether BT13 similarly to GDNF43-46
increases striatal dopamine release in mouse brain using
brain microdialysis method. The infusion of 50 μM BT13
increased extracellular dopamine level in the striatum
(Fig. 5D) at 105 to165minutes (30minutes vs. 105minutes
P = 0.0160, 30 minutes vs. 120 minutes P = 0.0011,
30 minutes vs. 135 minutes P = 0.0013, 30 minutes
vs. 150 minutes P = 0.0015, 30 minutes vs. 165 minutes
P = 0.0091, 1-way ANOVA with Dunnett’s post hoc test)
from the beginning of the experiment (or approximately
75–135 minutes after the beginning of BT13 infusion). It is
important to note that the infusion of BT13 into the micro-
dialysis system started at the 30-minute timepoint, and it
took 60 minutes for BT13 to pass through the tubing.
Therefore, the effect ofBT13 reachedmaximum30minutes
after the entry of the first dose into the brain and remained
at practically the same level for the next 30 minutes,
followed by a gradual decrease. In the vehicle-treated mice,
FIG. 4. BT13 activates intracellular signaling cascades responsible for the survival and regeneration of neurons in vitro. Representative images
of dopamine neurons probed with anti-phospho-ERK (pERK) (A) and with anti-phospho-S6 (pS6) antibody (B). (C) Mean intensity of pERK
immunostaining in dopamine neurons in different treatment groups presented as percentage of vehicle-treated dopamine neurons. (D) Mean
intensity of pS6 immunostaining of dopamine neurons in different treatment groups presented as percentage of vehicle-treated dopamine neu-
rons. GDNF concentration, 10 ng/ml; BT13, 1 μM. One-way analysis of variance with Dunnett’s post hoc test. Mean  standard error of the mean.
Scale bar = 30 nm. Number of independent experiments (N) = 3. GDNF, glial cell line–derived neurotrophic factor; VEH, vehicle.
*P < 0.05, **P < 0.01.
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the level of extracellular dopamine remained stable during
the whole experiment (data not shown).
BT13 Penetrates the Blood–Brain Barrier and
Increases the Levels of Dopamine Metabolites
in the Midbrain
We evaluated the concentration of BT13 in the fron-
tal cortex, striatum, midbrain, cerebellum, and plasma
0.5 to 3 hours postintravenous administration. BT13
was detected in all 4 studied regions of the brain at con-
centrations exceeding the plasma’s by approximately
1.2 to 3 fold (Table S1). An analysis of dopamine and
dopamine metabolite content in the midbrain revealed
a statistically significant increase in the concentration of
HVA and a trend toward an increase in dopamine and
DOPAC concentrations in rats receiving intravenous
BT13 (Fig. S3).
FIG. 5. BT13 activates intracellular signaling cascades responsible for survival and regeneration of neurons in vivo and stimulates release of dopamine
in mouse striatum. (A) Representative images of coronal sections from mouse brains probed with anti-phospho-S6 (pS6, lower pictures) and anti-pho-
spho-ERK (pERK, upper pictures) antibodies. GDNF dose, 10 μg; BT13 dose, 750 μg. (B) Relative optical density of pERK immunostaining in the dorsal
striatum in different treatment groups presented as percentage of vehicle-treated side. (C) Relative optical density of pS6 immunostaining in the dorsal
striatum in different treatment groups presented as percentage of vehicle-treated side. Statistical significance for the differences between vehicle and
BT13/GDNF-injected sides was determined by paired 2-tailed Student’s t test. N = 3 to 4/group. Scale bar = 200 μm. (D) BT13 at 50 μM concentration
increased extracellular dopamine level, whereas the lower concentration (25 μM) had no effect. One-way analysis of variance with Dunnett’s post hoc
test. Mean  standard error of the mean. Number of animals (N) = 5/group. GDNF, glial cell line–derived neurotrophic factor; VEH, vehicle. *P < 0.05,
**P < 0.01. [Color figure can be viewed at wileyonlinelibrary.com]
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Discussion
We have characterized a small-molecule RET agonist,
BT13, in immortalized cells and in the dopamine system in
vitro and in vivo. In immortalized cells, BT13 had similar
efficacy to GFLs in RET, ERK, and AKT phosphorylation
assays (Fig. 1A–I); however, in integral luciferase assay the
effect of BT13 was much more modest compared with
GDNF or soluble GDNF/GFRα1 complex (Fig. 1J,K28,30).
This can be partly explained by the quick metabolism of
BT13.28 The efficacy of BT13 (100 nM and 1 μM) was
comparable with that of GDNF in its ability to support the
survival of cultured dopamine neurons (Fig. 2), to protect
them from 6-OHDA (Fig. 3A) and MPP+ -induced
cell death (Fig. 3B), and to increase pERK and pS6 levels
both in vitro (Fig. 4) and in vivo (Fig. 5). Nevertheless,
the potency of BT13 was 2 to 3 orders of magnitude lower
than that of GDNF, that is, GDNF supported the survival
of cultured dopamine neurons at approximately the 0.3
nM concentration. Notably, the concentrations of the
positive control proteins in all experiments were selected
on the basis of previous results and biological activity in
screening assay to produce clear effects in studied
systems.28,30,33,47,48
Importantly, both BT13 and GDNF promoted the sur-
vival of the primary dopamine neurons in lower concen-
trations than in immortalized cells. Artificial cell systems
differ from primary neurons in many ways. In particular,
the stoichiometry of relevant receptors, intracellular medi-
ators, and other factors may differ and thereby regulate
the sensitivity to agonists. The limited aqueous solubility
of BT13 prevented us from testing it in higher concentra-
tion (above 100 μM) in murine fibroblasts. Perhaps in
immortalized cells the full potential of BT13 to promote
phosphorylation of RET and intracellular signaling cas-
cades was not achieved because of its insufficient solubility
in the cell culturemedium.
Earlier, we showed that BT13 activates RET selec-
tively28; it is unable to stimulate other receptor tyrosine
kinases, for example, Tropomyosin receptor kinase B
(TrkB), a receptor for brain-derived neurotrophic factor,
which is a known survival factor for dopamine neurons;
TrkB-dependent activation of AKT and MAPK signaling
cascades or activation of AKT and ERK in the MG87
parental cells.49 Consistent with these data, in the present
study BT13 was unable to increase luciferase activity in
the reporter cell line lacking RET, whereas FGF2 activated
the reporter in these cells indicative of their functional
integrity (Fig. 1L). We also showed that the survival pro-
moting effect of BT13 in cultured dopamine neurons is
RET-dependent (Fig. 2B). BT13 similarly to GDNF is
unable to promote the survival of naïve and toxin-
challenged dopamine neurons lacking RET (Fig. 2C and
Fig. 3C). In addition, BT13 does not promote the survival
of GABA-positive neurons (Fig. S1), suggesting that BT13
is selective to dopamine neurons in midbrain cultures.
However, in contrast to GDNF, BT13 is a direct RET ago-
nist and it does not require a GFRα coreceptor to elicit bio-
logical effects (Fig. 1). Molecular dynamics simulation
studies demonstrated that the compound can bind on the
interface of RET andGFRα1.50 Therefore, BT13 can influ-
ence neurons expressing any combination of GFRα
coreceptors and RET, thus increasing the proportion of
responsive neurons.
The degeneration of dopamine neurons caused by
6-OHDA and MPP+ is often used to model PD and evalu-
ate neuroprotective properties of studied compounds in
vitro and in vivo. GDNF protects and restores dopamine
neurons in culture and in experimental animals upon treat-
ment with either of these neurotoxins.7,8,41,51,52 In the pre-
sent study, 1 μM BT13 similarly to GDNF showed
significant neuroprotection of RET-expressing dopamine
neurons against both 6-OHDA andMPP+ -induced degen-
eration (Fig. 3A,B). We also observed significant neuro-
protective effect of BT13 at a lower concentration (0.1 μM)
in 6-OHDA-treated dopamine neurons. In MPP+ -treated
dopamine neurons the number of survived cells had a ten-
dency to increase in response to 0.1 μM BT13, but this
effect was not statistically significant (P = 0.19). It should
be noted that the degeneration of dopamine neurons
induced byMPP+ in our experiments wasmilder compared
with the effect of 6-OHDA (Fig. 3). Therefore, a small effect
size could have prevented us from seeing significant effect
of lower concentration of BT13 in MPP+ in vitromodel of
PD. Alternatively, this discrepancy can be explained by the
fact that different toxin model might not respond in a simi-
lar way to different concentrations of BT13.
The neuroprotective and neurorestorative effects of
GDNF in dopamine neurons are mediated by activation
of intracellular pathways such as PI3K/AKT and MAPK,
which play a role in cell survival and differentiation.25,53-57
In the present study, we showed that 1 μM BT13 similarly
to GDNF activated ERK and AKT pathways in cultured
dopamine neurons (Fig. 4 and Fig. S2). It is important to
note that 1 μM BT13 also promoted the survival of näive
dopamine neurons (Fig. 2) and protected them from toxin-
induced death (Fig. 3). In addition, BT13 also significantly
activated ERK and AKT (assessed by pS6 level) pathways
when injected into the striatum of naïve animals (Fig. 5A–
C). Taken together, these in vitro and in vivo results sug-
gest that BT13 can play a potential role in the survival and
regeneration of dopamine neurons.
Microdialysis data show that infusion of BT13 into the
striatum increases extracellular dopamine level (Fig. 5D),
further indicating its ability to activate relevant signaling
pathways in the brain. Notably, GDNF overexpression
from the native locus enhances dopamine release in the stri-
atum of transgenic mice.39 Importantly, the ability of BT13
to elevate extracellular dopamine level may not correlate
with its neurotrophic activity. The effect on dopamine level
is possibly mediated through the inhibition of A-type potas-
sium channels that GDNF is known to regulate,58 but it
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may also be the consequence of dopamine transporter
(DAT) regulation that was recently characterized for
GDNF.59,60 The fact that the extracellular dopamine level
started to decrease after some time even though the infu-
sion continued suggests activation of homeostatic mecha-
nisms. These mechanisms might include alterations in the
availability or activity of GDNF receptors and/or DAT.61
We showed that systemically administered BT13 gets into
the brain that is in line with our previous findings28 and
reaches the nigrostriatal dopamine system (Table S1).
Moreover, it may influence dopamine content and metabo-
lism in the midbrain (Fig. S3). The limited aqueous solubil-
ity of BT13 and its quick metabolism28 likely restricted its
free concentration and duration of action in the brain after
bolus injection. Therefore, we observed only a trend in
some neurochemical parameters measured in our pilot
experiment with relatively small number of animals per
group. We noticed a statistically significant increase in
HVA level accompanied by a slight increase in the
HVA/DA ratio, which represents a sum of dopamine turn-
over and release,62 but no changes in theDOPAC/DA ratio,
which is an indicator of dopamine turnover63 30 minutes
posttreatment with BT13. Taken together, these data sug-
gest that BT13 affects dopamine release rather than dopa-
mine synthesis, which is consistent with microdialysis
experiment data (Fig. 5D). Based on the results of the phar-
macokinetic and neurochemical studies, we can conclude
that optimized BT13 derivatives with increased half-life and
better brain exposure should increase dopamine release in
nigrostriatal system also after systemic administration.
In conclusion, our data offer a proof of principle for
small-molecule synthetic RET agonists in in vitro neu-
rotoxin model of PD. Our first-generation compound
BT13 has promising effects on dopaminergic system
both in vitro and in vivo. We are currently improving
the potency and pharmacological properties of BT13
using medicinal chemistry methods to develop a lead
compound to test in animal models of PD.
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